Anktiva®: An FDA-Approved Game-Changer for Non-Muscle Invasive Bladder Cancer
The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA, a novel immunotherapy, in combination with Bacillus...
Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Authority FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Protocol Design Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA, a novel immunotherapy, in combination with Bacillus...
Azitra, a biopharmaceutical company specializing in dermatology therapies, announced promising preclinical data demonstrating the potential of its platform for...
Neurogene’s NGN-401 gene therapy for Rett syndrome has exhibited promising safety results in initial clinical trials. After several months...
Lantern Pharma has received regulatory approval to expand its Phase 2 clinical trial (HarmonicTM) to evaluate the efficacy of...
The European Commission has approved EMBLAVEO® (aztreonam-avibactam) as a treatment for severe infections caused by Gram-negative bacteria. This includes...
Two comprehensive studies have demonstrated the effectiveness of algorithm-driven alerts in optimizing antibiotic selection for hospitalized patients with pneumonia...
In a conversation with Ramita Tandon, Walgreens’ Chief Clinical Trials Officer, we explore the company’s cutting-edge strategies to maximize...
The U.S. Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the treatment of patients with ALK-positive non-small...
Oncodesign Precision Medicine (OPM) has received €5.6 million in funding for the DEMOCRITE project, aimed at demonstrating the efficacy...
Delve Bio and researchers at the University of California, San Francisco collaborated to showcase the potential of metagenomic next-generation...